NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, has announced that a Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected to commence soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from the local agency ACOREP and has appointed Professor Patrick Katoto as the principal investigator. Preparatory work, including staff training, is underway, and the NV-387 drug product is already available in the DRC, with first patient dosing anticipated within a few weeks, barring outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. The company believes that oral delivery could offer significant advantages in resource-limited outbreak settings compared to treatments requiring intravenous infusions. This is particularly relevant in the DRC, where healthcare infrastructure may be challenged by ongoing outbreaks. Om Sai Clinical Research Private Limited is serving as the contract research organization (CRO) for this trial, as well as for the company’s planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC.
The significance of this trial lies in its potential to provide a more practical treatment option for Ebola, which has historically been managed with intravenous therapies that require specialized medical staff and facilities. An oral formulation could be administered more easily in remote areas, potentially improving patient outcomes and reducing transmission. Moreover, the broad-spectrum nature of NV-387 means it may be effective against multiple viral strains, including the current Bundibugyo strain, which has caused recent outbreaks.
NanoViricides' technology is based on nanomedicine, creating special purpose nanomaterials that mimic host cell receptors to attract and neutralize viruses. The company's lead candidate, NV-387, is being developed for various viral infections, including respiratory syncytial virus (RSV), COVID-19, influenza, and Mpox. The company has a broad intellectual property portfolio and licenses technology from TheraCour Pharma, Inc. for specific applications. The path to drug approval is lengthy and requires substantial capital, and there is no assurance that NV-387 will prove safe and effective in clinical trials.
The start of this Phase II trial marks a critical step for NanoViricides in advancing its pipeline and addressing unmet medical needs in viral outbreaks. The company's focus on oral delivery could differentiate it from existing treatments and provide a scalable solution for pandemic preparedness. As the trial progresses, results will be closely watched by the medical and investment communities.
